Abstract
Dyslipidemia plays an important role in the initiation and progression of atherosclerotic coronary artery disease. However, regression of atherosclerotic atheroma by introducing lipid lowering agents is not fully understood but looks promising. More questions still need to be answered in terms of the modality of assessment, time course of changes and its documentation, whether plaque progression or regression assessed by imaging one arterial tree reflects a uniform effect throughout all arterial territories and whether atheroma regression is a therapeutic goal. Physicians need to define the type of statins, the use of statin as monotherapy or in combination with other agents, and the intensity of statin therapy. Furthermore, the impact of factors like age, gender and ethnicity on the regression process should be of consideration. We still need more randomized controlled studies based on evidence-based diagnostic interventional tools. This narrative review considers this debate.
Keywords: Atheroma, coronary artery disease, atherosclerosis, lipids, statins, regression.
Current Vascular Pharmacology
Title: Dyslipidemia, Vascular Atheroma and Statins
Volume: 13 Issue: 6
Author(s): Ahmed Abuzaid and Ayman El-Menyar
Affiliation:
Keywords: Atheroma, coronary artery disease, atherosclerosis, lipids, statins, regression.
Abstract: Dyslipidemia plays an important role in the initiation and progression of atherosclerotic coronary artery disease. However, regression of atherosclerotic atheroma by introducing lipid lowering agents is not fully understood but looks promising. More questions still need to be answered in terms of the modality of assessment, time course of changes and its documentation, whether plaque progression or regression assessed by imaging one arterial tree reflects a uniform effect throughout all arterial territories and whether atheroma regression is a therapeutic goal. Physicians need to define the type of statins, the use of statin as monotherapy or in combination with other agents, and the intensity of statin therapy. Furthermore, the impact of factors like age, gender and ethnicity on the regression process should be of consideration. We still need more randomized controlled studies based on evidence-based diagnostic interventional tools. This narrative review considers this debate.
Export Options
About this article
Cite this article as:
Abuzaid Ahmed and El-Menyar Ayman, Dyslipidemia, Vascular Atheroma and Statins, Current Vascular Pharmacology 2015; 13 (6) . https://dx.doi.org/10.2174/1570161112666141029224451
DOI https://dx.doi.org/10.2174/1570161112666141029224451 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Anti-Inflammatory Agents from Plants: Progress and Potential
Current Medicinal Chemistry Vascular Stiffness: Measurements, Mechanisms and Implications
Current Vascular Pharmacology New Insights into the Surgical Management of Tetralogy of Fallot: Physiological Fundamentals and Clinical Relevance
Current Pediatric Reviews Antihyperglycemic and Antidyslipidemic Activities of the <i>Aqueous Salvia hispanica</i> Extract in Diabetic Rat
Cardiovascular & Hematological Agents in Medicinal Chemistry Primary and Secondary Hypertriglyceridaemia
Current Drug Targets Meet Our Editorial Board Member
Current Vascular Pharmacology Momordica balsamina: A Medicinal and Neutraceutical Plant for Health Care Management
Current Pharmaceutical Biotechnology Endothelial Dysfunction and Inflammation in Ischemic Stroke Pathogenesis
Current Pharmaceutical Design Circulating MicroRNAs as Biomarkers for Inflammatory Diseases
MicroRNA A Developmental Approach to Drug-induced Liver Injury in Newborns and Children
Current Medicinal Chemistry Pharmacogenomics and Personalized Medicine for the Developing World - Too Soon or Just-in-Time? A Personal View from the World Health Organization
Current Pharmacogenomics and Personalized Medicine Markers of Early Vascular Ageing
Current Pharmaceutical Design Inflammation: A Novel Therapeutic Target/Direction in Atherosclerosis
Current Pharmaceutical Design Clinical Management of the Cardiovascular Failure in Sepsis
Current Vascular Pharmacology The Role of Venous Abnormalities in Neurological Disease
Reviews on Recent Clinical Trials Illuminating microRNA Transcription from the Epigenome
Current Genomics Averrhoa bilimbi L. leaf Aqueous Extract Modulates both Cardiac Contractility and Frequency in the Guinea-pig Atrium by the Activation of Muscarinic Receptors
Letters in Drug Design & Discovery Neurotrophic and Neuroprotective Effects of Muscle Contraction
Current Pharmaceutical Design Role of α -Crystallin B in Regulation of Stress Induced Cardiomyocyte Apoptosis
Cardiovascular & Hematological Agents in Medicinal Chemistry Biocatalysis in the Pharmaceutical Industry. A Greener Future
Current Green Chemistry